Detalhe da pesquisa
1.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
2.
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Invest New Drugs
; 37(2): 297-306, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132271
3.
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Am J Hematol
; 93(10): 1199-1206, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30016552
4.
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Ann Hematol
; 93(1): 89-98, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24135804
5.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069
6.
Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis.
Cancer Med
; 10(3): 1066-1073, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527779
7.
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
EJHaem
; 4(1): 301-304, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36819162